Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.01542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Ang Li und 20 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX. Hauptthemen laut MEDLINE: Venous Thromboembolism, Venous Thrombosis, Thrombosis, Pulmonary Embolism. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS.
Abstract (Originalsprache)
PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable complication for patients with cancer undergoing systemic therapy. METHODS Using retrospective data from patients diagnosed with incident cancer from 2011-2020, we derived a parsimonious risk assessment model (RAM) using least absolute shrinkage and selection operator regression from the Harris Health System (HHS, n = 9,769) and externally validated it using the Veterans Affairs (VA) health care system (n = 79,517). Bootstrapped c statistics and calibration curves were used to assess external model discrimination and fit. Dichotomized risk strata using integer scores were created and compared against the Khorana score (KS). RESULTS Incident VTE and PE/LE-DVT at 6 months occurred in 590 (6.2%) and 437 (4.6%) patients in HHS and 4,027 (5.1%) and 3,331 (4.2%) patients in the VA health care system. Assessed at the time of systemic therapy initiation, the new RAM included components of the KS with the modified cancer subtype, cancer staging, systemic therapy class, history of VTE, history of paralysis/immobility, recent hospitalization, and Asian/Pacific Islander race. The c statistic was 0.71 in HHS and 0.68 in the VA health care system (compared with 0.65 and 0.60, respectively, for KS). Furthermore, the new RAM appropriately reclassified 28% of patients and increased the proportion of VTEs in the high-risk group from 37% to 68% in the validation data set. CONCLUSION The novel RAM stratified patients with cancer into a high-risk group with 8%-10% cumulative incidence of VTE and 7% PE/LE-DVT at 6 months ( v 3% and 2%, respectively, in the low-risk group). The model had improved performance over the original KS and doubled the number of VTE events in the high-risk stratum. We encourage additional external validation from prospective studies. [Media: see text]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX.
- Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA.
- Institute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX.
- Section of Epidemiology and Population Science, Baylor College of Medicine, Houston, TX.
- Harris Health System, Houston, TX.
- School of Medicine, Baylor College of Medicine, Houston, TX.
ORCID-Profile: Ang Li, Jennifer La, Sarah B May, Wilson L da Costa, Christopher I Amos, Karen M Kurian, Daniel C R Chen, Nhan V Do, Carolina Granada, Nimrah Riaz, Vipul Chitalia, Marc Carrier, Christopher R Flowers, Neil A Zakai, Nathanael R Fillmore
Förderung
- NHLBI NIH HHS
- NIH HHS
Zitieren
APA
Li, A., La, J., May, S. B., Guffey, D., da Costa, W. L., Amos, C. I., Bandyo, R., Milner, E. M., Kurian, K. M., Chen, D. C. R., Do, N. V., Granada, C., Riaz, N., Brophy, M. T., Chitalia, V., Gaziano, J. M., Garcia, D. A., Carrier, M., Flowers, C. R., …, & Fillmore, N. R. (2023). Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01542
Vancouver
Li A, La J, May SB, Guffey D, da Costa WL, Amos CI, et al. Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.01542
BibTeX
@article{Li2023,
author = {Li, Ang and La, Jennifer and May, Sarah B and Guffey, Danielle and da Costa, Wilson L and Amos, Christopher I and Bandyo, Raka and Milner, Emily M and Kurian, Karen M and Chen, Daniel C R and Do, Nhan V and Granada, Carolina and Riaz, Nimrah and Brophy, Mary T and Chitalia, Vipul and Gaziano, J Michael and Garcia, David A and Carrier, Marc and Flowers, Christopher R and Zakai, Neil A and Fillmore, Nathanael R},
title = {Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.01542}
}
EUVIMED